The NIDUS-Family package of care uses goal setting to help people with dementia live well at home for longer. New research from Queen Mary University of London in collaboration with UCL shows that, in addition to these known benefits, NIDUS-Family also reduces the costs associated with providing support to people with dementia.

Approximately 982,000 people in the UK have dementia, and the costs of providing dementia support across health and social care are expected to rise to £90 billion by 2040. Finding ways to support people with dementia to continue to live in their own homes is likely to improve well-being, reduce inequalities in accessing treatment, and be cost-effective.

Designed by researchers at Queen Mary University of London, NIDUS-Family is a package of care and support which focuses on practical changes people can make, with sessions built around the specific priorities of the person with dementia—such as increasing time spent in enjoyable activities, improving sleep or for caregivers to have more time to focus on their own well-being.

It can be delivered to the person with dementia and family caregiver together, or the family caregiver alone, by phone, video-call or in person.

A randomised controlled trial, led by Claudia Cooper, Professor of Psychological Medicine at Queen Mary, found that family caregivers and the people with dementia they supported who received the NIDUS-family intervention were significantly more likely to achieve the goals they set than those who received their usual care over a year. This was true whether the intervention was delivered by video-call, phone or in-person.

New data from the study, published in Lancet Healthy Longevity, shows that NIDUS-Family is also the first personalised care and support intervention to demonstrate cost-effectiveness from the perspective of the quality of life of people with dementia.

People with dementia who took part cost the NHS and social care £8,934 (37%) less on average over one year than people who did not receive the additional help. These cost savings came about thanks to the person receiving the intervention spending less time in hospital and using less state-funded social care, compared with controls, costs of which far exceeded the modest £346 annual cost of this preventive intervention.

Professor Claudia Cooper said, "The new therapy has the potential to be rolled out to support consistent, evidence-based personalised dementia care across the NHS. Given NIDUS-family helps people with dementia and their families, and also costs less, it should be widely available within routine care."

Dr. Richard Oakley, Associate Director of Research and Innovation at Alzheimer's Society, said, "Dementia devastates lives and around one million people in the UK have the condition, yet there are very few widely available therapies offering personalised support to help people improve their day-to-day life and well-being.

"Therapies on offer tend to be expensive, difficult for people in remote areas to access, one-size-fits-all, and need to be delivered by clinicians, so are reliant on our over-stretched care system. That's why the NIDUS-Family program is a game-changing intervention for people with dementia ..."

"This research shows we have at our fingertips a cost-effective, realistic solution offering people living with dementia access to tailored, personalised support to achieve their own goals, which we would like to see as an option in routine care."

Senior author, Professor Rachael Hunter from the Research Department of Primary Care and Population Health, UCL, said, "Given the challenges associated with improving care for people living with dementia, it's great to see an intervention that delivers tangible benefits to patients and their families as well as potentially having a positive financial benefit to the NHS."

Co-author, Professor and Chair Helen Kales, from the UC Davis Health Department of Psychiatry and Behavioral Sciences, said, "Because dementia is such a prevalent syndrome that impacts the entire family, we urgently need evidence-based, low-cost interventions for families and people living with dementia.

"The trial results showing the cost-effectiveness of NIDUS-Family are very exciting. In the United States, this personalised intervention can inform care within the Centers for Medicare & Medicaid Services (CMS) new dementia model, Guiding an Improved Dementia Experience (GUIDE) Model sites."

The new therapy has the potential to be rolled out to support consistent, evidence-based personalised dementia care across the NHS. The findings coincide with a call from the All-Party Parliamentary Group (APPG) inquiry on dementia for a levelling up of diagnosis rates and the care people receive after a diagnosis, recommending that high-quality post-diagnostic support services for dementia must be available more equitably across England.

Although current national guidelines recommend that everyone with dementia receives personalised, post-diagnostic support, few do. Nearly two-thirds (61%) of those aged over 65 with dementia in the UK live in their own homes, rather than in care homes.

However, unmet needs, poor self-care, home safety risks and burden reported by family caregivers are common reasons necessitating a move to a care home.

More information: Abdinasir Isaaq, et al. Cost-utility of a new psychosocial goal-setting and manualised support intervention for Independence in Dementia (NIDUS-Family) versus goal-setting and routine care: economic evaluation embedded within a randomised controlled trial, The Lancet Healthy Longevity (2025). DOI: 10.1016/j.lanhl.2024.100676